High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H.

Abstract

T-cell prolymphocytic leukemia (T-PLL) is a chemotherapy-resistant malignancy with a median survival of 7.5 months. Preliminary results indicated a high remission induction rate with the human CD52 antibody, CAMPATH-1H. This study reports results in 39 patients with T-PLL treated with CAMPATH-1H between March 1993 and May 2000. All but 2 patients had… (More)

6 Figures and Tables

Topics

  • Presentations referencing similar topics